CABA Stock Analysis: Buy, Sell, or Hold?
CABA - Cabaletta Bio, Inc. Common Stock
$2.95
0.10 (3.70%)
▲
5d:
-2.16%
30d:
-9.94%
90d:
-3.13%
BUY
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CABA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CABA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CABA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CABA is currently trading at $2.94, which is considered oversold relative to its 30-day fair value range of $3.08 to $3.72.
Technical Outlook: Technically, CABA is in a downtrend. Immediate support is located at $2.77, while resistance sits at $3.51. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CABA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.38 (+371.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CABA is in a downtrend. Immediate support is located at $2.77, while resistance sits at $3.51. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CABA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.38 (+371.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.08 -
$3.72
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 371.0% below Wall St target ($13.38)
Trading Range Analysis
30-Day Trading Range
$3.08 -
$3.72
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.77
Resistance Level
$3.51
Current Trend
Downtrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.00
Wall Street Target
$13.38
(+371.0%)
Share & Embed Analysis
Last updated: June 18, 2026 3:11 PM ET
Data refreshes hourly during market hours. Next update: 4:11 PM
Data refreshes hourly during market hours. Next update: 4:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CABA showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David J Chang
BUY
8800 shares
2026-01-21
Gwendolyn Binder
BUY
11312 shares
2026-01-21
Mark Simon
BUY
11061 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 68 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 55 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 67 BUY |
